Executive leadership at VivoSim Labs.
Board of directors at VivoSim Labs.
Research analysts covering VivoSim Labs.
Recent press releases and 8-K filings for VIVS.
VivoSim Labs Expands Asia-Pacific Access to Toxicology Services
VIVS
New Projects/Investments
Revenue Acceleration/Inflection
- VivoSim Labs has appointed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind™ toxicology services in liver and small intestine.
- This expansion aims to provide faster access to human-relevant toxicology services across Asia-Pacific, with NAMKind™ offering a targeted 30-day turnaround time per compound.
- The collaboration with Tekon Biotech positions VivoSim to capitalize on China's in-vitro toxicology testing market, which is projected to grow significantly from approximately $1.05 billion in 2023 to $2.26 billion by 2030.
- The company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (FDA) announcement on April 10, 2025, to refine animal testing requirements in favor of non-animal New Approach Methodologies (NAMs).
Jan 29, 2026, 9:05 PM
Quarterly earnings call transcripts for VivoSim Labs.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more